Results 51 to 60 of about 19,369 (169)

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

Translational Oncology
Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare, resulting in most pediatric treatment recommendations being based on data derived from adults.
Colin H. Quinn, Andee M. Beierle, Adele P. Williams, Raoud Marayati, Laura V. Bownes, Hooper R. Market, Michael E. Erwin, Jamie M. Aye, Jerry E. Stewart, Elizabeth Mroczek-Musulman, Karina J. Yoon, Elizabeth A. Beierle   +11 more
doaj   +1 more source

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Cell Reports, 2013
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not ...
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson   +27 more
doaj   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source

Hypertrophic Cardiomyopathy as a Key Feature of MRAS‐Related Noonan Syndrome: New Case and Comprehensive Literature Review

Prenatal Diagnosis, EarlyView.
ABSTRACT Noonan syndrome (NS) is a rare multisystemic condition among the RASopathy group, characterized by a broad phenotypic spectrum and genetic variability. It results from pathogenic variants in genes regulating the RAS/MAPK pathway, affecting cell proliferation and differentiation.
Romain Martineau, Constance Wells, Florent Fuchs, Sophie Collardeau‐Frachon, Valentin Ruault, Sophie Colomb, Jean‐Michel Faure, Caroline Bartholmot, Marie Vincenti, Benjamin Ganne, Marjolaine Willems   +10 more
wiley   +1 more source

QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid‐Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 561-571, March 2025.
ABSTRACT Type 2 diabetes mellitus (T2DM), characterized by insulin resistance, is closely associated with Alzheimer's disease (AD). Cerebrovascular dysfunction is manifested in both T2DM and AD, and is often considered as a pathological link between the two diseases.
Zengtao Wang, Vaishnavi Veerareddy, Xiaojiao Tang, Kevin J. Thompson, Sunil Krishnan, Krishna R. Kalari, Karunya K. Kandimalla   +6 more
wiley   +1 more source

Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature

Frontiers in Oncology
Dissemination in pediatric low-grade glioma may occur in about 4%–10% of patients according to retrospective cohort studies. Due to its low incidence, there is no consensus on treatment for these patients.
Serafin Castellano-Damaso, Felisa Vazquez-Gomez, Jose Luis Moreno-Carrasco, Begoña Arce, Pedro Borrego, Alvaro Lassaletta   +5 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Identification of novel FGFR2::TXLNB Fusion in a polymorphous low‐grade neuroepithelial tumor of the young

Brain Pathology, EarlyView.
We report a novel FGFR2::TXLNB fusion in a child with hippocampal PLNTY. This fusion likely drives tumorigenesis via homodimerization and activation of MAPK/PI3K pathways, expanding PLNTY's molecular spectrum and suggesting a potential therapeutic target.
Sha‐Sha Hu, Tian‐Yuan Tan, Wei Yan, Bo Wang   +3 more
wiley   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source